Among these, EMPA-REG OUTCOME, the CANVAS Program, DECLARE-TIMI 58, and the CREDENCE trial did not specifically enroll patients with heart failure, but a meta-analysis of these studies demonstrated a protective effect of SGLT2 inhibitors with respect to CV death/MI/stroke (RR, 0.81; 95% CI, 0.70–0.94) and heart failure as well (RR, 0.61; 95% CI, 0.48–0.78) [124]. The gene discussed is SLC5A2; the disease is heart failure.